Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.

Check Now !

Warm Autoimmune Hemolytic Anemia Waiha Market

DelveInsight’s ‘Warm Autoimmune Hemolytic Anemia – Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the wAIHA, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan.

 

The Warm Autoimmune Hemolytic Anemia market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted wAIHA symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Warm Autoimmune Hemolytic Anemia symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5
  • Japan

Study Period: 2018–2030

Warm Autoimmune Hemolytic Anemia Disease Understanding and Treatment Algorithm

Warm Autoimmune Hemolytic Anemia Overview

Autoimmune hemolytic anemia (AIHA) is an acquired hemolytic disorder where antibodies directed against red blood cell (RBC) surface epitopes cause premature RBC destruction, which leads to anemia. Although rare, AIHA is one of the most common forms of acquired hemolytic disorders. AIHA can occur at any age but is most common among older adults, and the majority of AIHA individuals are above 40 years at diagnosis.

 

AIHAs may be primary (idiopathic) or secondary associated with several conditions (lymphoproliferative, autoimmune and infectious diseases, immunodeficiencies, solid tumors, transplants, and drugs) where the cited immunologic mechanisms are variably combined. Diagnosis may be easy, but some rare forms may be challenging, causing harmful delays in initiating appropriate therapy. Based on the isotype and thermal characteristics of the autoantibody, AIHA has been traditionally divided into warm forms, cold agglutinin disease (CAD), and rarer forms—mixed, atypical and paroxysmal cold hemoglobinuria.

 

Warm autoimmune hemolytic anemia (wAIHA) is the most common type of autoimmune hemolytic anemia, comprising approximately 70–80% of all adult cases and 50% of the pediatric cases. More than half of these cases are called primary due to undefined etiology.

 

For a long time, wAIHA had been viewed as a rare autoimmune disease that could be treated empirically, on a long-term basis, mainly by corticosteroids. Due to some informative observational studies and efforts made in the classification of wAIHA (primary vs. secondary), the natural history and prognosis of the disease are henceforth better known.

 

wAIHA is a chronic disease. Even after response to steroids, individuals have a >60% probability of relapse after steroid tapering and withdrawal. Further understanding of the pathogenesis and the variability of the disease will be necessary to optimally tailor individualized treatment strategies with the goal of optimal efficacy with the lowest possible short- and long-term toxicity

 

Warm Autoimmune Hemolytic Anemia Diagnosis and Treatment

It covers conventional and current medical therapies and diagnosis available in the wAIHA market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the 7MM.

 

The DelveInsight wAIHA market report thoroughly understands wAIHA symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides wAIHA symptoms of treatment algorithms and treatment guidelines for wAIHA symptoms in the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan.

Warm Autoimmune Hemolytic Anemia Epidemiology

The epidemiology division’s wAIHA symptoms provide insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted wAIHA epidemiology segmented as the Total Prevalent Cases of Autoimmune Hemolytic Anemia, Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia, Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia, Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia. The report includes the prevalent wAIHA symptoms in the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

 

Total prevalent population of Warm Autoimmune Hemolytic Anemia in 7 major markets was found to be  89,747 cases in 2020.

Warm Autoimmune Hemolytic Anemia Drug Chapters

The drug chapter segment of the wAIHA report encloses the detailed analysis of wAIHA marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the wAIHA clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

The mainstay of treatment remains symptomatic and supportive – Affected individuals are usually treated with corticosteroid drugs such as prednisone and can usually be well controlled with proper treatment. The first-line treatment of w-AIHA includes glucocorticosteroids and transfusion. The first dose of steroids should be given immediately after the call that DAT is positive.

 

The traditional treatment options for WAIHA include corticosteroids, splenectomy, and conventional immunosuppressive drugs. Over the years, however, newer options have become available with considerable evidence of success.

Products detail in the report…

 

Warm Autoimmune Hemolytic Anemia Emerging Drugs

 

Rigel Pharmaceuticals is developing R935788 for the treatment of wAIHA based on the significant medical need. R935788 is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK). It is currently in Phase III clinical trial for treatment of Warm Antibody Autoimmune Hemolytic Anemia.

Warm Autoimmune Hemolytic Anemia Market Outlook

The wAIHA market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Psoriasis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

 

This segment gives a thorough detail of wAIHA market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight clearly.

 

According to DelveInsight, the Warm Autoimmune Hemolytic Anemia market in the 7MM is expected to change in the study period 2018–2030.

 

Key Findings

This section includes a glimpse of the wAIHA market in the United States. The market size of wAIHA in the United States was USD 297 Million in 2020, and the market is estimated to increase  during the study period (2018–2030).

 

The United States Market Outlook

This section provides a total of wAIHA market size and market size by therapies in the United States.

 

The pipeline scenario is showing early promise with several therapeutic candidates at different stages of clinical development. Many new therapies for wAIHA are in development, many of which have novel targets and mechanisms of action. Among the emerging drugs, Fostamatinib is in the late development stages.

 

Apart from that, APL-2 is currently in the Phase II stage of clinical development.

 

EU-5 Countries: Market Outlook

The total wAIHA market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided.

 

Japan: Market Outlook

The total Psoriasis market size and market size by therapies in Japan are also mentioned.

Warm Autoimmune Hemolytic Anemia Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers wAIHA market uptake by drugs, patient uptake by therapies, and drug sales.

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows comparing the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Warm Autoimmune Hemolytic Anemia Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses wAIHA key players involved in developing targeted therapeutics.

 

Major players include Fostamitinib (Rigel Pharmaceuticals), and APL-2 (Apellis Pharmaceuticals),  M281 (Janssen Pharmaceuticals) etc. and being assessed as potential therapies available in the market in the future

Products detail in the report…

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for wAIHA emerging therapies.

Reimbursement Scenario in Warm Autoimmune Hemolytic Anemia

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to ensure that the patient receives Social Security Disability benefits as quickly as possible and help the patient avoid the lengthy disability appeal process.

KOL  Views

To keep up with current market trends, we take KOLs and SME’s opinion working in AIHA domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the wAIHA market trend. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the wAIHA Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of wAIHA, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the wAIHA epidemiology and treatment in the  United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • Additionally, an all-inclusive account of both the current and emerging therapies for wAIHA is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the wAIHA market; historical and forecasted is included in the report, covering drug outreach in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global wAIHA market

Report Highlights

  • In the coming years, the wAIHA market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence wAIHA R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for wAIHA. The launch of emerging therapies will significantly impact the wAIHA market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for wAIHA.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Warm Autoimmune Hemolytic Anemia Report Insights

  • Patient Population
  • Therapeutic Approaches
  • wAIHA Pipeline Analysis
  • wAIHA Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Warm Autoimmune Hemolytic Anemia Report Key Strengths

  • 10-year Forecast
  • The United States Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Market Size by Country
  • Market Size by Therapy

Warm Autoimmune Hemolytic Anemia Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Emerging Drug Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Psoriasis Market share (%) distribution in 2018, and how it would look like in 2030?
  • What would be the Psoriasis total market Size as well as market Size by therapies across the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan during the forecast period (2018–2030)?
  • What are the market’s key findings across the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan and historical as well as forecasted epidemiology during the forecast period (2018–2030)?
  • At what CAGR, the Psoriasis market is expected to grow by the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan during the forecast period (2018–2030)?
  • What would be the Psoriasis market outlook across the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan during the forecast period (2018–2030)?
  • What would be the Psoriasis market growth till 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of psoriasis?
  • What is the historical WAIHA patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of wAIHA in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about wAIHA?
  • At what CAGR the population is expected to grow during the forecast period (2018–2030)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of wAIHA?
  • What are the current treatment guidelines for treating wAIHA in the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What are wAIHA marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of wAIHA?
  • How many therapies are developed by each company for the treatment of wAIHA?
  • How many emerging therapies are in the mid-stage and late stages of development to treat wAIHA?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the WAIHA therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for wAIHA and its status?
  • What are the key designations that have been granted for the emerging therapies for wAIHA?
  • What are the global historical and forecasted market of wAIHA?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the WAIHA market
  • To understand the future market competition in the WAIHA market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for WAIHA in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for WAIHA market
  • To understand the future market competition in the WAIHA market

1. Key Insights

2. Report Introduction

3. wAIHA Market Overview at a Glance

3.1. Market Share (%) Distribution of wAIHA in 2018

3.2. Market Share (%) Distribution of wAIHA in 2030

4. Executive Summary of Warm Autoimmune Hemolytic Anemia

5. Disease Background and Overview

5.1. Introduction

5.2. Signs and Symptoms

5.3. Classification

5.4. Causes

5.5. Pathophysiology

5.6. Clinical Manifestation

5.7. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Patient Population of Warm Autoimmune Hemolytic Anemia

6.3. Assumption and Rationale: 7MM

6.4. The United States

6.4.1. Total Prevalent Cases of Autoimmune Hemolytic Anemia in the US

6.4.2. Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in the US

6.4.3. Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the US

6.4.4. Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the US

6.5. EU5

6.5.1. Germany

6.5.1.1. Total Prevalent Cases of Autoimmune Hemolytic Anemia in Germany

6.5.1.2. Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in Germany

6.5.1.3. Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Germany

6.5.1.4. Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Germany

6.5.2. France

6.5.2.1. Total Prevalent Cases of Autoimmune Hemolytic Anemia in France

6.5.2.2. Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in France

6.5.2.3. Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in France

6.5.2.4. Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in France

6.5.3. Italy

6.5.3.1. Total Prevalent Cases of Autoimmune Hemolytic Anemia in Italy

6.5.3.2. Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in Italy

6.5.3.3. Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Italy

6.5.3.4. Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Italy

6.5.4. Spain

6.5.4.1. Total Prevalent Cases of Autoimmune Hemolytic Anemia in Spain

6.5.4.2. Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in Spain

6.5.4.3. Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Spain

6.5.4.4. Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Spain

6.5.5. United Kingdom

6.5.5.1. Total Prevalent Cases of Autoimmune Hemolytic Anemia in the UK

6.5.5.2. Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in the UK

6.5.5.3. Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the UK

6.5.5.4. Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the UK

6.6. Japan

6.6.1. Total Prevalent Cases of Autoimmune Hemolytic Anemia in Japan

6.6.2. Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in Japan

6.6.3. Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Japan

6.6.4. Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Japan

7. Treatment and Management

7.1. Sequential Approach to Treatment Options for wAIHA and common dosing regimens

7.2. British Guidelines for wAIHA treatment

8. Organizations contributing toward WAIHA

9. Case Report

10. Patient Journey

11. Emerging Therapies

11.1. Fostamatinib: Rigel Pharmaceuticals

11.1.1. Drug Description

11.1.2. Product Development

11.1.3. Clinical Development

11.1.3.1. Clinical Trials Information

11.1.4. Safety and Efficacy

11.1.5. Product Profile

11.2. APL-2: Apellis Pharmaceuticals, Inc.

11.2.1. Drug Description

11.2.2. Regulatory Milestone

11.2.3. Product Development

11.2.4. Clinical Development

11.2.4.1. Clinical Trials Information

11.2.5. Safety and Efficacy

11.2.6. Product Profile

11.3. M281: Johnson & Johnson

11.3.1. Drug Description

11.3.2. Product Development

11.3.3. Clinical Development

11.3.3.1. Clinical Trials Information

11.3.4. Safety and Efficacy

11.3.5. Product Profile

11.4. IMVT-1401: Immunovant

11.4.1. Drug Description

11.4.2. Product Development

11.4.3. Clinical Development

11.4.3.1. Clinical Trials Information

11.4.4. Safety and Efficacy

11.4.5. Product Profile

11.5. ALXN1830/SYNT001: Alexion Pharmaceuticals

11.5.1. Drug Description

11.5.2. Product Development

11.5.3. Clinical Development

11.5.3.1. Clinical Trials Information

11.5.4. Product Profile

11.6. BIVV009 (Sutimlimab): Sanofi

11.6.1. Drug Description

11.6.2. Product Development

11.6.3. Clinical Development

11.6.3.1. Clinical Trials Information

11.6.4. Safety and Efficacy

11.6.5. Product Profile

11.7. Parsaclisib: Incyte Corporation

11.7.1. Drug Description

11.7.2. Clinical Development

11.7.2.1. Clinical Trials Information

11.7.3. Safety and Efficacy

11.7.4. Product Profile

11.8. Rilzabrutinib: Sanofi

11.8.1. Drug Description

11.8.2. Product Development

11.8.3. Clinical Development

11.8.3.1. Clinical Trials Information

11.8.4. Product Profile

11.9. Isatuximab: Sanofi

11.9.1. Drug Description

11.9.2. Product Development

11.9.3. Clinical Development

11.9.3.1. Clinical Trials Information

11.9.4. Product Profile

11.10. ANX005: Annexon

11.10.1. Drug Description

11.10.2. Clinical Development

11.10.2.1. Clinical Trials Information

11.10.3. Product Profile

12. Warm Autoimmune Hemolytic Anemia: 7 Major Market Analysis

12.1. Key Findings

12.2. Market Size of Warm Autoimmune Hemolytic Anemia in the 7MM

12.3. Market Size by Therapies in the 7MM

13. Country-wise Market Analysis

13.1. Market Outlook

13.2. United States Market Size

13.2.1. Total Market Size of Warm Autoimmune Hemolytic Anemia by Class in the US

13.2.2. Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in the US

13.2.3. Germany

13.2.3.1. Total Market size of Warm Autoimmune Hemolytic Anemia in Germany

13.2.3.2. Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in Germany

13.2.4. France

13.2.4.1. Total Market size of Warm Autoimmune Hemolytic Anemia in France

13.2.4.2. Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in France

13.2.5. Italy

13.2.5.1. Total Market size of Warm Autoimmune Hemolytic Anemia in Italy

13.2.5.2. Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in Italy

13.2.6. Spain

13.2.6.1. Total Market size of Warm Autoimmune Hemolytic Anemia in Spain

13.2.6.2. Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in Spain

13.2.7. United Kingdom

13.2.7.1. Total Market size of Warm Autoimmune Hemolytic Anemia in the UK

13.2.7.2. Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in the UK

13.3. Japan

13.3.1. Total Market size of Warm Autoimmune Hemolytic Anemia in Japan

13.3.2. Market Size of Warm Autoimmune Hemolytic Anemia by Therapies in Japan

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. Unmet Needs

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Tables

Table 1: Summary of Warm Autoimmune Hemolytic Anemia, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Prevalent Patient Population of wAIHA in the 7MM (2018–2030)

Table 3: Total Prevalent Cases of Warm Autoimmune Hemolytic Anemia in the US in thousands (2018–2030)

Table 4: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in the US in thousands (2018–2030)

Table 5: Type-specific Cases of Warm Autoimmune Hemolytic Anemia in the US (2018–2030)

Table 6: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the US (2018–2030)

Table 7: Total Prevalent Cases of Autoimmune Hemolytic Anemia in Germany in thousands (2018–2030)

Table 8: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in Germany (2018–2030)

Table 9: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Germany (2018–2030)

Table 10: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Germany (2018–2030)

Table 11: Total Prevalent Cases of Autoimmune Hemolytic Anemia in France (2018–2030)

Table 12: Diagnosed Prevalence of of Warm Autoimmune Hemolytic Anemia in France (2018–2030)

Table 13: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in France (2018–2030)

Table 14: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in France (2018–2030)

Table 15: Total Prevalent Cases of Autoimmune Hemolytic Anemia in Italy (2018–2030)

Table 16: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in Italy (2018–2030)

Table 17: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Italy (2018–2030)

Table 18: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Italy (2018–2030)

Table 19: Total Prevalent Cases of Autoimmune Hemolytic Anemia in Spain (2018–2030)

Table 20: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in Spain (2018–2030)

Table 21: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Spain (2018–2030)

Table 22: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Spain (2018–2030)

Table 23: Total Prevalent Cases of Autoimmune Hemolytic Anemia  in the UK (2018–2030)

Table 24: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in the UK (2018–2030)

Table 25: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the UK (2018–2030)

Table 26: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the UK (2018–2030)

Table 27: Total Prevalent Cases of Autoimmune Hemolytic Anemia  in Japan (2018–2030)

Table 28: Diagnosed Pevalence of Warm Autoimmune Hemolytic Anemia in Japan (2018–2030)

Table 29: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Japan (2018–2030)

Table 30: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Japan (2018–2030)

Table 31: Treatment Flow

Table 32: Organizations contributing toward wAIHA

Table 33: Fostamatinib, Clinical Trial Description, 2021

Table 34: APL-2, Clinical Trial Description, 2021

Table 35: M281, Clinical Trial Description, 2021

Table 36: IMVT-1401, Clinical Trial Description, 2021

Table 37: ALXN1830/ SYNT001, Clinical Trial Description, 2021

Table 38: BIVV009, Clinical Trial Description, 2021

Table 39: Parsaclisib, Clinical Trial Description, 2021

Table 40: Rilzabrutinib, Clinical Trial Description, 2021

Table 41: Isatuximab, Clinical Trial Description, 2021

Table 42: ANX005 Clinical Trial Description, 2021

Table 43: 7 Major Market Size of Warm Autoimmune Hemolytic Anemia in USD Million (2018–2030)

Table 44: 7MM Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2018–2030)

Table 45: The US Market Size of Warm Autoimmune Hemolytic Anemia by Class in USD Million (2018–2030)

Table 46: The US Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2018–2030)

Table 47: Germany Market Size of Warm Autoimmune Hemolytic Anemia in USD Million (2018–2030)

Table 48: Germany Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2018–2030)

Table 49: France Market Size of Warm Autoimmune Hemolytic Anemia by in USD Million (2018–2030)

Table 50: France Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2018–2030)

Table 51: Italy Market Size of Warm Autoimmune Hemolytic Anemia in USD Million (2018–2030)

Table 52: Italy Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2018–2030)

Table 53: Spain Market Size of Warm Autoimmune Hemolytic Anemia in USD Million (2018–2030)

Table 54: Spain Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2018–2030)

Table 55: The UK Market Size of Warm Autoimmune Hemolytic Anemia in USD Million (2018–2030)

Table 56: The UK Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2018–2030)

Table 57: Japan Market Size of Warm Autoimmune Hemolytic Anemia in USD Million (2018–2030)

Table 58: Japan Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2018–2030)

List of figures

Figure 1: Classification of wAIHA

Figure 2: Mechanisms of Hemolysis IN Warm Antibody Autoimmune Hemolytic Anemia

Figure 3: Mechanisms of Hemolysis in Warm Antibody Autoimmune Hemolytic Anemia

Figure 4: Direct Antiglobulin Test

Figure 5: Total Prevalent Patient Population of wAIHA in the 7MM (2018–2030)

Figure 6: Total Prevalent Cases of AIHA in the US (2018–2030)

Figure 7: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in the US (2018–2030)

Figure 8: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the US (2018–2030)

Figure 9: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the US (2018–2030)

Figure 10: Total Prevalent Cases of Autoimmune Hemolytic Anemia in Germany (2018–2030)

Figure 11: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in Germany (2018–2030)

Figure 12: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Germany (2018–2030)

Figure 13: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Germany (2018–2030)

Figure 14: Total Prevalent Cases of Autoimmune Hemolytic Anemia in France (2018–2030)

Figure 15: Diagnosed Prevalence of of Warm Autoimmune Hemolytic Anemia in France (2018–2030)

Figure 16: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in France (2018–2030)

Figure 17: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in France (2018–2030)

Figure 18: Total Prevalent Cases of Autoimmune Hemolytic Anemia in Italy (2018–2030)

Figure 19: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in Italy (2018–2030)

Figure 20: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Italy (2018–2030)

Figure 21: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Italy (2018–2030)

Figure 22: Total Prevalent Cases of Autoimmune Hemolytic Anemia in Spain (2018–2030)

Figure 23: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in Spain (2018–2030)

Figure 24: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Spain (2018–2030)

Figure 25: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Spain in thousands (2018–2030)

Figure 26: Total Prevalent Cases of Autoimmune Hemolytic Anemia in the UK (2018–2030)

Figure 27: Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia in the UK (2018–2030)

Figure 28: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the UK (2018–2030)

Figure 29: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in the UK (2018–2030)

Figure 30: Total Prevalent Cases of Autoimmune Hemolytic Anemia in Japan (2018–2030)

Figure 31: Diagnosed Pevalence of Warm Autoimmune Hemolytic Anemia in Japan (2018–2030)

Figure 32: Type-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Japan (2018–2030)

Figure 33: Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia in Japan (2018–2030)

Figure 34: Treatment algorithm for warm AIHA in adults

Figure 35: 7 Major Market Size of Warm Autoimmune Hemolytic Anemia in USD Million (2018–2030)

Figure 36: Market Size by Therapies in USD Million (2018–2030)

Figure 37: The US Market Size of Warm Autoimmune Hemolytic Anemia by Class, USD Million (2018–2030)

Figure 38: The US Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2018–2030)

Figure 39: Germany Market Size of Warm Autoimmune Hemolytic Anemia, USD Million (2018–2030)

Figure 40: Germany Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2018–2030)

Figure 41: France Market Size of Warm Autoimmune Hemolytic Anemia, USD Million (2018–2030)

Figure 42: France Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2018–2030)

Figure 43: Italy Market Size of Warm Autoimmune Hemolytic Anemia, USD Million (2018–2030)

Figure 44: Italy Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2018–2030)

Figure 45: Spain Market Size of Warm Autoimmune Hemolytic Anemia, USD Million (2018–2030)

Figure 46: Spain Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2018–2030)

Figure 47: The UK Market Size of Warm Autoimmune Hemolytic Anemia, USD Million (2018–2030)

Figure 48: The UK Market Size of Warm Autoimmune Hemolytic Anemia by Emerging therapies in USD Million (2018–2030)

Figure 49: Japan Market Size of Warm Autoimmune Hemolytic Anemia in USD Million (2018–2030)

Figure 50: Japan Market Size of Warm Autoimmune Hemolytic Anemia by Therapies in USD Million (2018–2030)

Rigel Pharmaceuticals
Apellis Pharmaceuticals, Inc.
Johnson & Johnson
Immunovant
Alexion Pharmaceuticals
Sanofi
Incyte Corporation
Annexon

 

Forward to Friend

Need A Quote